Alvotech (ICE:ALVO)

Iceland flag Iceland · Delayed Price · Currency is ISK
1,055.00
+35.00 (3.43%)
At close: Oct 7, 2025
3.43%
Market Cap328.05B
Revenue (ttm)68.10B
Net Income (ttm)7.67B
Shares Outn/a
EPS (ttm)26.33
PE Ratio42.77
Forward PE19.11
Dividendn/a
Ex-Dividend Daten/a
Volume191,301
Average Volume95,563
Open1,030.00
Previous Close1,020.00
Day's Range1,025.00 - 1,075.00
52-Week Range946.00 - 1,945.00
Beta0.10
RSI58.19
Earnings DateNov 12, 2025

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]

Sector Healthcare
Founded 2013
Employees 1,012
Stock Exchange Nasdaq Iceland
Ticker Symbol ALVO
Full Company Profile

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD Financial Statements

News

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

16 days ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK,  ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...

16 days ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

16 days ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK,  ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...

16 days ago - GlobeNewsWire

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

19 days ago - GlobeNewsWire

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK,  ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...

19 days ago - GlobeNewsWire

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech (NASDAQ:ALVO) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Balaji Prasad - Chief Strategy Officer Conference Call Participants...

4 weeks ago - Seeking Alpha

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

4 weeks ago - GlobeNewsWire

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland,  June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today it...

4 weeks ago - GlobeNewsWire

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...

6 weeks ago - GlobeNewsWire

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide a...

6 weeks ago - GlobeNewsWire

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK,  ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce...

7 weeks ago - GlobeNewsWire

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

7 weeks ago - Seeking Alpha

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...

2 months ago - GlobeNewsWire

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

2 months ago - GlobeNewsWire

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today t...

2 months ago - GlobeNewsWire

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, a...

2 months ago - GlobeNewsWire

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

REYKJAVIK,  ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced ...

3 months ago - GlobeNewsWire

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

3 months ago - GlobeNewsWire

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

REYKJAVIK,  ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wo...

3 months ago - GlobeNewsWire

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

REYKJAVIK, Iceland and BURGDORF, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicine...

3 months ago - GlobeNewsWire

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voti...

3 months ago - GlobeNewsWire

Granting of Stock Options and Vesting of Restricted Share Units

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company's Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four ...

3 months ago - GlobeNewsWire

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

3 months ago - GlobeNewsWire

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

REYKJAVIK,  ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and...

3 months ago - GlobeNewsWire